You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (6) |
Back to Search
Identification of a novel inhibitor for hepatitis B virus internalization targeting viral receptor oligomerization
- At: PSWC2020 (2020)
- Type: Poster
- By: FUKANO, Kento (National Institute of Infectious Diseases, Department of Virology II, Japan)
- Co-author(s): Kento Fukano: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
Senko Tsukuda: Liver Cancer Prevention Research Unit, Center for Integrative Medical Sciences, RIKEN, Saitama, Japan;Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
Mizuki Oshima: Department of Applied Biological Science, Tokyo University of Science, Chiba, Japan;Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
Mio Ohki: Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan
Sam-Yong Park: Drug Design Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan
Kousho Wakae: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
Hideki Aizaki: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
Takaji Wakita: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
Koichi Watashi: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan;Department of Applied Biological Science, Tokyo University of Science, Chiba, Japan
Masamichi Muramatsu: Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan - Abstract:
Background
Current anti-HBV agents including nucleos(t)ide analogs and interferons can reduce the viral load, but are not generally curative. Thus, the development of anti-HBV agents with different modes of action is required to improve treatment outcomes.Purpose
In this study, we aim to identify small molecules inhibiting HBV internalization as.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026